Advertisement

Topics

Otsuka Pharma Release: ABILIFY MAINTENA (Aripiprazole) For Extended-Release Injectable Suspension Approved By U.S. FDA For Maintenance Monotherapy Treatment Of Bipolar I Disorder

20:00 EDT 30 Jul 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Otsuka Pharma Release: ABILIFY MAINTENA (Aripiprazole) For Extended-Release Injectable Suspension Approved By U.S. FDA For Maintenance Monotherapy Treatment Of Bipolar I Disorder

NEXT ARTICLE

More From BioPortfolio on "Otsuka Pharma Release: ABILIFY MAINTENA (Aripiprazole) For Extended-Release Injectable Suspension Approved By U.S. FDA For Maintenance Monotherapy Treatment Of Bipolar I Disorder"

Quick Search
Advertisement